Statements

Letter to Private Sector Clinicians Regarding FDC

This letter is from the Southern African HIV Clinicians Society to clinicians in the private sector regarding the prescribing of FDC tablets to public sector patients including the approach and management for phasing in the FDC treatment.

Letter to Public Sector Clinicians Regarding FDC

This is a letter from the South African HIV Clinicians Society to public sector clinicians regarding private sector patients transferring in on the FDC tablets, including the approach and management to be taken to introducing FDC treatment.

The U.S. Women and PrEP Working Group's Response to the VOICE Trial Results

The U.S. Women and PrEP Working Group, a coalition of more than 50 women from leading AIDS and women’s health organizations, released the following document in response to the results of the VOICE trial.

Understanding the Results of the VOICE Trial by MTN

The Microbicide Trials Network (MTN) prepared the following document to aid in understanding the results of the VOICE trial.

Results of VOICE Study by MTN

The Microbicide Trials Network released the following results of a major HIV prevention trial, known as the VOICE trial. The results suggest that daily use of a product – whether a vaginal gel or an oral tablet – does not appear to be the right approach for preventing HIV in young, unmarried African women.

CDC Statement in Response to VOICE Trial Results

In wake of latest trial results, the CDC stresses that consistent use is imperative when using Pre-Exposure Prophylaxis to prevent HIV infection. This statement can be attributed to Jonathan Mermin, M.D., Director of CDC’s Division of HIV/AIDS Prevention

Statement by Child and adolescent Committee of SAHIV Clinicians Society regarding Functional cure of HIV positive child in USA

Child and adolescent committee of SAHIV Clinicians Society made the following statement regarding the announcement of the first documented case of a child cured of HIV that took place at the 2013 Conference on Retroviruses and Opportunistic Infections (CROI) in Atlanta on March 4 2013.